RecruitingPhase 2Phase 3NCT06604273

Unravelling Intestinal Fibrosis in Ulcerative Colitis

Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Enrollment

10 participants

Start Date

Apr 3, 2024

Study Type

INTERVENTIONAL

Conditions

Fibroblast Activation Protein Inhibitor Ulcerative Colitis (UC)Inflammatory Bowel Disease (IBD)

Summary

The main objectives are: (i) to identify candidate fibrotic cellular pathways in UC patients treated with a JAK inhibitor filgotinib), and (ii) to detect and monitor in vivo fibrosis in UC patients using FAPi-PET/CT imaging

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating how scarring (fibrosis) develops in the intestines of people with ulcerative colitis (UC), a type of inflammatory bowel disease that causes chronic inflammation in the colon. Researchers want to understand why scarring occurs and how it progresses, especially in patients starting a specific medication called filgotinib. **You may be eligible if...** - You are 18 years or older (males must be 30+, females 40+, for one group) - You have a confirmed diagnosis of ulcerative colitis - Your disease is currently active, based on colonoscopy results - You are about to start treatment with filgotinib - You have signs of active disease on ultrasound or elevated inflammation markers in blood or stool tests **You may NOT be eligible if...** - You are pregnant - You cannot give informed consent - You have colorectal cancer or high-grade pre-cancerous cells Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.